- $31.39m
- -$53.24m
- $2.41m
- 65
- 47
- 48
- 53
Annual income statement for Akso Health, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
R2020 March 31st | R2021 March 31st | R2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 6.91 | 0 | 6 | 13.2 | 2.41 |
| Cost of Revenue | |||||
| Gross Profit | — | 0 | 0.605 | 1.27 | 0.122 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 55 | 4.24 | 9.26 | 27.4 | 11.1 |
| Operating Profit | -48.1 | -4.24 | -3.26 | -14.3 | -8.64 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -46.9 | -4.29 | -4.01 | -13.1 | -9.09 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -47.4 | -4.29 | -4.1 | -13.1 | -9.12 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -71.2 | -34.8 | -16.9 | -1.36 | -9.46 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -71.2 | -34.8 | -16.9 | -1.36 | -9.46 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.582 | -0.088 | -0.069 | -0.192 | -0.064 |